Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 341

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 341
---
 |
| Total lease cost       |     | $            | 2,380 |     | $ |  207 |

F-18

Lease commitments Future minimum lease payments were as follows (in thousands):

| Year ended December 31,                      
 2024                                         |     | Amount |  1,897 |   |
|:---------------------------------------------|:----|:-------|-------:|:--|
| 2025                                         |     |        |  2,128 |   |
| 2026                                         |     |        |  2,190 |   |
| 2027                                         |     |        |  2,253 |   |
| 2028                                         |     |        |  2,319 |   |
| Thereafter                                   |     |        |  4,632 |   |
| Total future minimum lease payments          |     |        | 15,419 |   |
| Less imputed interest                        |     |        | (4,942 | ) |
| Present value of operating lease liabilities |     | $      | 10,477 |   |

8. Commitments and Contingencies Operating Leases The Company has entered into arrangements for leases of office space; see Note 7, “Leases,” for details. Legal Proceedings The Company was not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and the Company is not aware of any material legal proceedings that are currently pending or threatened. License Agreements The Company entered into licenses agreements under which it is obligated to make fixed and contingent payments; see Note 9 “License Agreements” and Note 16 “Subsequent Events” for details. Other Contracts The Company is party to various contracts with CROs and contract manufacturing organizations that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. Based on our development plans as of December 31, 2023, the Company may be obligated to make future development and commercial milestone payments, and royalty payments on future sales of specified products associated with the Company’s license agreements (refer to Note 9). Payments under these agreements generally become due and payable upon achievement of such milestones or sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in the Company’s consolidated financial statements. There were no contractual obligations arising from these arrangements as of December